{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:26:14Z","timestamp":1790832374075,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.vaccine.2014.08.051","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T09:37:59Z","timestamp":1409909879000},"page":"5769-5775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)"],"prefix":"10.1016","volume":"32","author":[{"given":"Stephen J.","family":"Seligman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.08.051_bib0005","first-page":"870","volume":"38","year":"2012"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.051_bib0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2010.10-0001","article-title":"Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States","volume":"82","author":"Monath","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"9276","key":"10.1016\/j.vaccine.2014.08.051_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"issue":"9276","key":"10.1016\/j.vaccine.2014.08.051_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"issue":"9276","key":"10.1016\/j.vaccine.2014.08.051_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.vaccine.2014.08.051_bib0030","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.051_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4269\/ajtmh.13-0542","article-title":"Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data","volume":"90","author":"Seligman","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"22","key":"10.1016\/j.vaccine.2014.08.051_bib0040","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever\u2014challenges for the development and use of vaccines","volume":"357","author":"Monath","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0050","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59(RR-7)","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"9438","key":"10.1016\/j.vaccine.2014.08.051_bib0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","article-title":"History of thymoma and yellow fever vaccination","volume":"364","author":"Barwick","year":"2004","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.vaccine.2014.08.051_bib0060","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2014.08.051_bib0065","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2014.08.051_bib0070","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3201\/eid1710.101789","article-title":"Yellow fever virus vaccine-associated deaths in young women","volume":"17","author":"Seligman","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.051_bib0075","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/QAI.0b013e318249de59","article-title":"Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients","volume":"59","author":"Pacanowski","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1349","key":"10.1016\/j.vaccine.2014.08.051_bib0085","first-page":"92","article-title":"A case of yellow fever vaccine-associated disease","volume":"125","author":"Isenman","year":"2012","journal-title":"NZ Med J"},{"issue":"33","key":"10.1016\/j.vaccine.2014.08.051_bib0090","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2014.08.051_bib0095","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.051_bib0100","first-page":"156","article-title":"Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan","volume":"23","author":"Fitzner","year":"2004","journal-title":"Ivory Coast Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2014.08.051_bib0105","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"9296","key":"10.1016\/j.vaccine.2014.08.051_bib0110","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(01)06917-3","article-title":"Effects of yellow fever vaccination","volume":"358","author":"Werfel","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2014.08.051_bib0115","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7205\/MILMED-D-11-00304","article-title":"Yellow fever vaccine-associated viscerotropic disease","volume":"177","author":"Rowland","year":"2012","journal-title":"Mil Med"},{"issue":"48","key":"10.1016\/j.vaccine.2014.08.051_bib0125","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2014.08.051_bib0130","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0135","series-title":"Serious events supposedly attributable to vaccination or immunization associated with receipt of yellow fever vaccine during a Mass Immunization Campaign Peru, 2007","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.provac.2010.07.012","article-title":"Yellow fever vaccine post-marketing surveillance in Brazil","volume":"2","author":"de Menezes Martins","year":"2010","journal-title":"Procedia Vaccinol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0002-9343(74)90487-2","article-title":"Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia","volume":"56","author":"Sutton","year":"1974","journal-title":"Am J Med"},{"issue":"50","key":"10.1016\/j.vaccine.2014.08.051_bib0150","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0155","first-page":"959","volume":"36","year":"2008"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.051_bib0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain","volume":"36","author":"Doblas","year":"2006","journal-title":"J Clin Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.051_bib0165","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2013-01-474213","article-title":"Autoantibodies against cytokines: back to human genetics","volume":"121","author":"Puel","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1084\/jem.190.4.479","article-title":"Direct evidence for thymic function in adult humans","volume":"190","author":"Poulin","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.01.015","article-title":"Yellow fever vaccine-associated adverse events following extensive immunization in Argentina (in press)","author":"Biscayart","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2014.08.051_bib0180","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1172\/JCI38111","article-title":"Human genetics of infectious diseases: between proof of principle and paradigm","volume":"119","author":"Alcais","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.08.051_bib0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-genom-091212-153448","article-title":"The genetic theory of infectious diseases: a brief history and selected illustrations","volume":"14","author":"Casanova","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"11","key":"10.1016\/j.vaccine.2014.08.051_bib0190","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1084\/jem.20101597","article-title":"Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma","volume":"207","author":"Byun","year":"2010","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.051_bib0195","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes","volume":"198","author":"Pulendran","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.051_bib0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ng0597-100","article-title":"Global distribution of the CCR5 gene 32-basepair deletion","volume":"16","author":"Martinson","year":"1997","journal-title":"Nat Genet"},{"issue":"6593","key":"10.1016\/j.vaccine.2014.08.051_bib0205","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.051_bib0210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcv.2006.12.011","article-title":"Fulminant hepatitis in dengue haemorrhagic fever","volume":"38","author":"Ling","year":"2007","journal-title":"J Clin Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T03:21:26Z","timestamp":1538277686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14011748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":42,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0264410X14011748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}